Therapy challenges for NMOSD in a patient with HIV
- PMID: 37712413
- PMCID: PMC10687800
- DOI: 10.1177/13524585231199022
Therapy challenges for NMOSD in a patient with HIV
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) in people living with HIV (PLWH) is rare and its management can be difficult. Here we report a case of an HIV patient with bilateral vision loss, who was diagnosed with AQP4-IgG-positive NMOSD in 2020 during the COVID-19 pandemic. Rituximab treatment was initiated after attack therapy with corticosteroids and plasma exchange. NMOSD and HIV disease remained stable, but SARS-CoV-2 immune response after repeated vaccinations was insufficient. After switching immunotherapy due to the lack of vaccination response to satralizumab, peripheral B cells reoccurred and a humoral immune response was observed after reapplication of SARS-CoV-2 vaccination. This case illustrates the challenges associated with the treatment of NMOSD in PLWH.
Keywords: HIV; Neuromyelitis optica (NMO); rituximab; satralizumab.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: DE received speaker honoraria from Alexion/AstraZeneca, JH reports grants for OCT research from the Friedrich-Baur-Stiftung and Merck, personal fees and non-financial support from Celgene, Janssen, Bayer, Merck, Alexion, Novartis, Roche, Biogen, Horizon and non-financial support of the Guthy-Jackson Charitable Foundation, all outside the submitted work, SF has no conflict of interest related to this work, TK has received speaker honoraria and/or personal fees for advisory boards from Roche Pharma, Alexion/Astra Zeneca, Horizon, Chugai and Biogen.
Figures

Similar articles
-
Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.Mult Scler Relat Disord. 2022 Feb;58:103414. doi: 10.1016/j.msard.2021.103414. Epub 2021 Nov 18. Mult Scler Relat Disord. 2022. PMID: 35216789
-
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.CNS Drugs. 2023 Apr;37(4):363-370. doi: 10.1007/s40263-023-00995-9. Epub 2023 Mar 18. CNS Drugs. 2023. PMID: 36933107 Review.
-
COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.Mult Scler Relat Disord. 2022 Sep;65:104003. doi: 10.1016/j.msard.2022.104003. Epub 2022 Jun 26. Mult Scler Relat Disord. 2022. PMID: 35803084 Free PMC article.
-
Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?Mult Scler Relat Disord. 2022 Oct;66:104035. doi: 10.1016/j.msard.2022.104035. Epub 2022 Jul 5. Mult Scler Relat Disord. 2022. PMID: 35858498 Free PMC article.
-
Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.Front Immunol. 2023 Oct 17;14:1257955. doi: 10.3389/fimmu.2023.1257955. eCollection 2023. Front Immunol. 2023. PMID: 37915570 Free PMC article.
References
-
- Bhigjee AI, Moodley AA, Roos I, et al.. The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa. South Afr J HIV Med 2017; 18(1): a684. https://sajhivmed.org.za/index.php/hivmed/article/view/684 (accessed 24 November 2022). - PMC - PubMed
-
- Nomah DK, Reyes-Urueña J, Diaz Y, et al.. CD4+ T-cell count below 200 cells/mm3 is associated with worse COVID-19 outcomes among people living with HIV regardless of virological suppression. https://onlinelibrary.wiley.com/doi/10.1002/jia2.25755 (accessed 24 November 2022). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous